title: Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
abstract: This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma focuses on adjuvant therapy and treatment of in-transit disease, because substantial changes were made to the recommendations for the 2016 update. Depending on the stage of the disease, options for adjuvant therapy now include biochemotherapy and high-dose ipilimumab. Treatment options for in-transit disease now include intralesional injection with talimogene laherparepvec (T-VEC), a new immunotherapy. These additions prompted re-assessment of the data supporting older recommended treatment options for adjuvant therapy and in-transit disease, resulting in extensive revisions to the supporting discussion sections.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Coit
authors.forename: John A
authors.initials: JA
authors.lastname: Thompson
authors.forename: Alain
authors.initials: A
authors.lastname: Algazi
authors.forename: Robert
authors.initials: R
authors.lastname: Andtbacka
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Bichakjian
authors.forename: William E
authors.initials: WE
authors.lastname: Carson
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Daniels
authors.forename: Dominick
authors.initials: D
authors.lastname: DiMaio
authors.forename: Marc
authors.initials: M
authors.lastname: Ernstoff
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Fields
authors.forename: Martin D
authors.initials: MD
authors.lastname: Fleming
authors.forename: Rene
authors.initials: R
authors.lastname: Gonzalez
authors.forename: Valerie
authors.initials: V
authors.lastname: Guild
authors.forename: Allan C
authors.initials: AC
authors.lastname: Halpern
authors.forename: F Stephen
authors.initials: FS
authors.lastname: Hodi
authors.forename: Richard W
authors.initials: RW
authors.lastname: Joseph
authors.forename: Julie R
authors.initials: JR
authors.lastname: Lange
authors.forename: Mary C
authors.initials: MC
authors.lastname: Martini
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Materin
authors.forename: Anthony J
authors.initials: AJ
authors.lastname: Olszanski
authors.forename: Merrick I
authors.initials: MI
authors.lastname: Ross
authors.forename: April K
authors.initials: AK
authors.lastname: Salama
authors.forename: Joseph
authors.initials: J
authors.lastname: Skitzki
authors.forename: Jeff
authors.initials: J
authors.lastname: Sosman
authors.forename: Susan M
authors.initials: SM
authors.lastname: Swetter
authors.forename: Kenneth K
authors.initials: KK
authors.lastname: Tanabe
authors.forename: Javier F
authors.initials: JF
authors.lastname: Torres-Roca
authors.forename: Vijay
authors.initials: V
authors.lastname: Trisal
authors.forename: Marshall M
authors.initials: MM
authors.lastname: Urist
authors.forename: Nicole
authors.initials: N
authors.lastname: McMillian
authors.forename: Anita
authors.initials: A
authors.lastname: Engh
mesh_terms: D006801:Humans; D008545:Melanoma / Q000175:diagnosis* / Q000628:therapy*